We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+31.97%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$1.12B
AUM Growth
-$319M
(-22%)
Cap. Flow
-$563M
Cap. Flow
% of AUM
-50.08%
Top 10 Holdings %
Top 10 Hldgs %
21.26%
Holding
360
New
82
Increased
64
Reduced
136
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$15.3M |
| 2 |
Broadridge
BR
|
+$13.9M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$11.1M |
| 4 |
Dominion Energy
D
|
+$10.6M |
| 5 |
NextEra Energy
NEE
|
+$9.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CORE
Core Mark Holding Co., Inc.
CORE
|
+$34M |
| 2 |
Zurn Elkay Water Solutions
ZWS
|
+$26.8M |
| 3 |
Rio Tinto
RIO
|
+$26.3M |
| 4 |
TriMas Corp
TRS
|
+$23.6M |
| 5 |
Texas Instruments
TXN
|
+$23.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.12% |
| 2 | Technology | 14.48% |
| 3 | Financials | 14% |
| 4 | Industrials | 10.81% |
| 5 | Healthcare | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Carvana
CVNA
$43.3B
| $1.23M | 0.11% |
51,140
-45,225
| -47% | -$847K |
|
152
KLA
KLAC
$275B
| $1.21M | 0.11% |
+62,090
| New | +$1.06M |
|
153
Twist Bioscience
TWST
$5.62B
| $1.2M | 0.11% |
26,392
+4,867
| +23% | +$175K |
|
154
Duke Energy
DUK
$102B
| $1.19M | 0.11% |
+14,925
| New | +$1.26M |
|
155
Natera
NTRA
$37.5B
| $1.19M | 0.11% |
23,805
+1,622
| +7% | +$65.1K |
|
156
Malibu Boats
MBUU
$544M
| $1.19M | 0.11% |
22,801
+10,674
| +88% | +$426K |
|
157
FormFactor
FORM
$8.11B
| $1.17M | 0.1% |
39,914
-291
| -0.7% | -$7.18K |
|
158
Vanguard FTSE Developed Markets ETF
VEA
$226B
| $1.17M | 0.1% |
30,074
-2,570
| -8% | -$93.8K |
|
159
Blue Owl Capital
OBDC
$5.35B
| $1.15M | 0.1% |
+93,437
| New | +$1.15M |
|
160
Cerence
CRNC
$382M
| $1.14M | 0.1% |
27,851
-6,489
| -19% | -$186K |
|
161
Axsome Therapeutics
AXSM
$12.4B
| $1.13M | 0.1% |
13,740
+7,734
| +129% | +$595K |
|
162
Palomar
PLMR
$3.65B
| $1.13M | 0.1% |
13,188
+2,089
| +19% | +$139K |
|
163
Fox Class B
FOX
$20.7B
| $1.11M | 0.1% |
41,433
-16,831
| -29% | -$447K |
|
|
TPTX
164
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $1.11M | 0.1% |
17,147
+3,853
| +29% | +$222K |
|
165
CRISPR Therapeutics
CRSP
$4.58B
| $1.07M | 0.1% |
+14,545
| New | +$850K |
|
166
Tesla
TSLA
$1.24T
| $1.07M | 0.09% |
14,820
-2,460
| -14% | -$133K |
|
167
Verizon
VZ
$194B
| $1.06M | 0.09% |
19,285
-29,008
| -60% | -$1.63M |
|
|
PING
168
DELISTED
Ping Identity Holding Corp.
PING
| $1.06M | 0.09% |
+33,042
| New | +$875K |
|
169
WisdomTree True Developed International Fund
DOL
$813M
| $1.05M | 0.09% |
25,850
-4,860
| -16% | -$190K |
|
170
Acadia Pharmaceuticals
ACAD
$4.25B
| $991K | 0.09% |
20,439
+5
| +0% | +$240 |
|
|
XLRN
171
DELISTED
Acceleron Pharma
XLRN
| $981K | 0.09% |
10,300
+1,941
| +23% | +$187K |
|
172
Ryman Hospitality Properties
RHP
$8.4B
| $976K | 0.09% |
+28,209
| New | +$936K |
|
173
AT&T
T
$165B
| $974K | 0.09% |
42,646
| – | – |
|
174
Capital Southwest
CSWC
$1.46B
| $962K | 0.09% |
71,380
+3,306
| +5% | +$42.7K |
|
175
Starbucks
SBUX
$118B
| $956K | 0.09% |
12,992
-11,554
| -47% | -$868K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q2 2020 Portfolio in Review
As of Q2 2020, Advisory Research held 360 positions worth $1.12B, down 22% from $1.44B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Advisory Research withdrew a net $563M in Q2 2020, closing 54 positions and reducing 136 holdings. Its most notable exit was Chunghwa Telecom, an estimated $18.4M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 18% a quarter earlier, followed by Technology and Financials.
Against the trend, Advisory Research opened a new position in AbbVie worth $17M.
- Advisory Research's largest Q2 2020 buy was AbbVie: 173,370 shares worth $17M.
- Advisory Research added most to Motorola Solutions in Q2 2020, an estimated $5.55M increase.
- Advisory Research's biggest Q2 2020 reduction was Core Mark Holding Co., Inc., cutting an estimated $34M.
- Advisory Research fully exited Chunghwa Telecom in Q2 2020, selling an estimated $18.4M.
- Advisory Research's ten largest holdings make up 21% of its $1.12B portfolio in Q2 2020.
- Advisory Research opened 82 new positions and closed 54 in Q2 2020.
- Advisory Research's portfolio value fell 22% quarter-over-quarter to $1.12B.
Based on Advisory Research's 13F filing for Q2 2020, filed 13 Aug 2020.